- JD Health reported first-half revenue of 28.34 billion yuan.
- Revenue fell short of the estimated 29.2 billion yuan.
- The company’s net income was 2.04 billion yuan.
- Earnings per share (EPS) were 65 RMB cents.
- Non-IFRS profit stood at 2.64 billion yuan.
- Research and development (R&D) expenses were 645.0 million yuan.
- R&D expenses were lower than the estimated 677.7 million yuan.
- Analyst ratings comprised 19 buys, 3 holds, and 2 sells.
A look at JD Health International Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 1 | |
| Growth | 5 | |
| Resilience | 5 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
JD Health International Inc., a company specializing in the retail of pharmaceutical and health products in China, seems to have a promising long-term outlook based on its Smartkarma Smart Scores. With impressive ratings in growth and resilience, scoring a 5 in both categories, JD Health International is poised for substantial development and has shown robustness in the face of challenges. Additionally, the company received a high score of 4 in the value category, reflecting strong fundamentals and potential for value creation. However, its momentum score of 2 suggests a need for improvement in this area to enhance market performance.
Overall, JD Health International is positioned favorably for the future, particularly considering its solid scores in growth and resilience. This indicates that the company not only has the potential for significant expansion but also possesses the ability to weather uncertainties effectively. While areas such as dividend yield and momentum could be areas of focus for further enhancement, JD Health International’s overall outlook appears positive, showcasing a strong foundation for sustained success in the competitive healthcare industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
